{"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"251"},{"groupId":"BG002","value":"498"}],"units":"Participants"}],"groups":[{"description":"Participants received bortezomib 1.3 milligrams per square meter (mg/m\\^2) subcutaneous (SC) injection on Days 1, 4, 8, and 11 of each 21-day cycle (8 treatment cycles) and dexamethasone 20 milligrams (mg) orally (PO) on Days 1, 2, 4, 5, 8, 9, 11, and 12 of the first 8 bortezomib treatment cycles. Participants who met sponsor confirmed disease progression eligibility criteria received daratumumab monotherapy as a subsequent antimyeloma therapy as follow: daratumumab 16 milligrams per kilogram (mg/kg) intravenous (IV) infusion or daratumumab SC injection (1800 mg fixed dose) weekly for the first 2 cycles, every 2 weeks from Cycle 3 to 6, and then every 4 weeks thereafter.","id":"BG000","title":"Bortezomib + Dexamethasone (Vd)"},{"description":"Participants received daratumumab 16 mg/kg IV infusion weekly or daratumumab SC injection (1800 mg fixed dose) for the first 3 cycles, on Day 1 of Cycles 4-8, and then every 4 weeks thereafter, bortezomib 1.3 mg/m\\^2 SC injection administration on Days 1, 4, 8, and 11 of each 21-day cycle (8 treatment cycles) and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 of the first 8 bortezomib treatment cycles.","id":"BG001","title":"Daratumumab + Bortezomib and Dexamethasone (DVd)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.81","value":"63.9"},{"groupId":"BG001","spread":"9.66","value":"62.8"},{"groupId":"BG002","spread":"9.74","value":"63.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"114"},{"groupId":"BG002","value":"213"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"137"},{"groupId":"BG002","value":"285"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"43"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"22"}]}],"title":"Brazil"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"35"}]}],"title":"Czech Republic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"42"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"30"}]}],"title":"Hungary"},{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"49"}]}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"18"}]}],"title":"Korea, Republic of"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}],"title":"Mexico"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"25"}]}],"title":"Netherlands"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"34"}]}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"34"}]}],"title":"Russian Federation"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"29"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"19"}]}],"title":"Sweden"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"28"}]}],"title":"Turkey"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"50"}]}],"title":"Ukraine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"37"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"96"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"194"}]}],"title":"I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"94"},{"groupId":"BG002","value":"194"}]}],"title":"II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"110"}]}],"title":"III"}],"description":"The International Staging System (ISS) system consists of stage I: beta2-microglobulin less than (\\<) 3.5 milligrams per liter(mg/L) and albumin greater than or equal to (\\>=) 3.5 grams (g) per 100 mL; stage II: neither stage I nor stage III and stage III:beta2-microglobulin \\>= 5.5 mg/L. The higher of staging, the worst of outcome.","paramType":"NUMBER","title":"Stage of Disease (ISS)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"235"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"144"}]}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"69"}]}],"title":"3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"50"}]}],"title":">3"}],"paramType":"NUMBER","title":"No. of Prior Lines of Therapy","unitOfMeasure":"participants"}]}